Aethlon Medical Appoints Pedro Cuatrecasas, MD, to Scientific Advisory Board

Business Wire, Jan 28, 2004

Business Editors/Health/Medical Writers

LA JOLLA, Calif.--(BUSINESS WIRE)--Jan. 28, 2004

Aethlon Medical, Inc. (OTCBB:AEMD) announced today that Pedro Cuatrecasas, MD, has been appointed to the Company's Science Advisory Board.

Dr. Cuatrecasas was President of the Pharmaceutical Research Division of Parke-Davis Co., and Corporate Vice President for Warner Lambert Company from 1989 until his retirement in 1997. From 1986 to 1989, he served as Sr. Vice President and Director of Glaxo Inc. For the prior ten years, he was Vice President of Research and Development and Director, of the Burroughs Wellcome Company.

During his career in pharmaceutical research, he was involved in the discovery, development and marketing registration of more than forty novel medicines, including: zidovudine (AZT, AIDS), acyclovir (Zovirax, anti-herpes), permethrin (Rid, head and body lice), bupropion (Wellbutrin, antidepressant), calsfosceril (Exosurf, infant acute respiratory distress), remifentanil (Ultiva, analgesic/anesthetic), sumatriptan (Imigran, migraine), salmeterol (Serement, asthma), tacrine (Cognex, Alzheimers), gabapentin (Neurontin, epilepsy and neuropathic pain), troglitazone (Rezulin, diabetes), and atorvastatin (Lipitor, cholesterol lowering).

Dr. Cuatrecasas is widely recognized for the invention and development of affinity chromatography, a process utilized within the Aethlon Hemopurifier(TM). He is a member of the National Academy of Sciences, The Institute of Medicine, and the American Academy of Arts & Sciences. He is a past recipient of the Wolf Prize in Medicine, the Washington University School Of Medicine Alumni Achievement Award, the Johns Hopkins University Distinguished Alumnus Award, the City of Medicine Award, and the North Carolina Governor's Medal Award in Science. Dr. Cuatrecasas has authored over 400 original publications.

About Aethlon Medical

Aethlon Medical is pioneering the development of viral filtration devices that reduce the presence of infectious disease and toxins in the body. To date, the Company has published pre-clinical results of its Hemopurifier(TM) to treat HIV/AIDS, and Hepatitis-C (HCV). The HIV-Hemopurifier removed 55% of HIV from human blood in three hours, and in excess of 85% in twelve hours. The HIV-Hemopurifier also cleared 90% of toxic proteins (gp-120) known to deplete immune cells in one hour. The HCV-Hemopurifier was documented to remove 58% of the Hepatitis-C virus from infected blood in two hours. The Hemopurifier(TM) is a proprietary platform technology that converges the established principles of affinity chromatography and hemodialysis as a means to augment the immune response of clearing viruses and toxins from human blood before cell and organ infection can occur. For additional information, visit the company's Web site at www.AethlonMedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.